On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy . KJ, who has a serious and rare genetic condition called severe carbamoyl phosphate synthetase 1 (CPS1), received two doses of a base editor bound to a bespoke targeting guide sequence using lipid nanoparticles (LNPs) when he was 7 and 8 months old. Around two months after the second infusion, KJ was discharged with his parents, Nicole and Kyle, accompanied by a police escort.

KJ’s case was brought to the world’s attention on May 15, 2025, when Kiran Musunuru, MD, PhD, presented it in a plenary session at the American Society for Gene and Cell Therapy (ASGCT) in New Orleans. Th

See Full Page